The new psoriasis drug Secukinumab (Cosentyx), a IL-17A-inhibiting antibody, approved by the FDA

The new psoriasis drug Secukinumab (Cosentyx), a IL-17A-inhibiting antibody, approved by the FDA
Atlethe's Foot

Last Updated on March 4, 2016 by Joseph Gut – thasso

January 21, 2015 –  On this day, the U.S. Food and Drug Administration has approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis.  Psoriasis is a skin condition that causes patches of skin redness and irritation. Psoriasis is an autoimmune disorder, and occurs more commonly in patients in with a family history of the disease, and most often begins in people between the ages of 15 and 35. The most common form of psoriasis is plaque psoriasis, in which patients develop thick, red skin with flaky, silver-white patches called scales.

Cosentyx’s active ingredient is secukinumab. Secukinumab is an antibody that binds to a protein (interleukin (IL)-17A) which is involved in inflammation. By binding to IL-17A, secukinumab prevents it from binding to its receptor, and inhibits its ability to trigger the inflammatory response that plays a role in the development of plaque psoriasis.

Ribbon model of the Interleukin 17 molecule
Ribbon model of the Interleukin 17 molecule

Cosentyx is administered as an injection under the skin. It is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or injected), phototherapy (ultraviolet light treatment) or a combination of both.  “Plaque psoriasis can cause significant skin irritation and discomfort for patients, so it is important to have a variety of treatment options available to patients,” said Amy Egan, M.D., M.P.H., deputy director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research. Cosentyx’s safety and effectiveness were established in four clinical trials with a total of 2,403 participants with plaque psoriasis who were candidates for phototherapy or systemic therapy. Participants were randomly assigned to receive Cosentyx or a placebo. The results showed that Cosentyx achieved greater clinical response than placebo, with skin that was clear or almost clear, as assessed by scoring of the extent, nature and severity of psoriatic changes of the skin.

Cosentyx is being approved with a Medication Guide to inform patients that, because Cosentyx is a medicine that affects the immune system, patients may have a greater risk of getting an infection. Serious allergic reactions have been reported with the use of Cosentyx. Caution should be exercised when considering the use of Cosentyx in patients with a chronic infection or history of recurrent infection, and in patients with active Crohn’s Disease. The most common side effects include diarrhea and upper respiratory infections.

Print Friendly, PDF & Email

Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

3 Comments on “The new psoriasis drug Secukinumab (Cosentyx), a IL-17A-inhibiting antibody, approved by the FDA

  1. Thanks for the video. I have had my whole life. Based on my own experience After I elaminited ALL PROCESSED FOODS from my diet my is totally under control. My SKIN HAS NEVER BEEN BETTER!! I drink GREEN TEA not coffee anymore. I don’t need prescription cortisone ointments. Aveeno Eczema Therapy is excellent! I eat mostly ORGANIC PRODUCE especially Plain ORGANIC YOGURT. I cut out ALL SUGAR. SUGAR is toxic. I didn’t realize how bad it is for you until I stopped eating it. THANKS!

  2. I love your blog.. very nice colors & theme. Did you create this website yourself or did you hire someone to do it for you?
    Plz answer back as I’m looking to design my own blog and would like to
    find out where u got this from. many thanks

    • Thank you for your liking my blog and website design. Yes, I did it all myself. I am not a web designer or programmer; actually I was learning things along the way. What I certainly like is to keep a website very simple and uncluttered. Contact me at for more info/details if you wish. Thanks.